Adverse events1,712

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 1,712

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	Placebo-Controlled Phase: Laquinimod 0.6 mg	28	727	32
other	Anaemia	Blood and lymphatic system disorders	Placebo-Controlled Phase: Laquinimod 1.2 mg	43	732	50
other	Anaemia	Blood and lymphatic system disorders	Placebo-Controlled Phase: Placebo	30	740	35
other	Anaemia	Blood and lymphatic system disorders	Active Treatment Phase: Early Laquinimod 0.6 mg	22	580	25
other	Anaemia	Blood and lymphatic system disorders	Active Treatment Phase: Early Laquinimod 1.2 mg	13	268	16
other	Anaemia	Blood and lymphatic system disorders	Active Treatment Phase: Off Drug	7	215	7
other	Anaemia	Blood and lymphatic system disorders	Active Treatment Phase: From Placebo to Laquinimod 0.6 mg	9	311	9
other	Anaemia	Blood and lymphatic system disorders	Active Treatment Phase: From Placebo to Laquinimod 1.2 mg	9	236	12
other	Nasopharyngitis	Infections and infestations	Placebo-Controlled Phase: Laquinimod 0.6 mg	63	727	90
other	Nasopharyngitis	Infections and infestations	Placebo-Controlled Phase: Laquinimod 1.2 mg	60	732	86
other	Nasopharyngitis	Infections and infestations	Placebo-Controlled Phase: Placebo	63	740	91
other	Nasopharyngitis	Infections and infestations	Active Treatment Phase: Early Laquinimod 0.6 mg	40	580	52
other	Nasopharyngitis	Infections and infestations	Active Treatment Phase: Early Laquinimod 1.2 mg	14	268	20
other	Nasopharyngitis	Infections and infestations	Active Treatment Phase: Off Drug	8	215	13
other	Nasopharyngitis	Infections and infestations	Active Treatment Phase: From Placebo to Laquinimod 0.6 mg	11	311	13
other	Nasopharyngitis	Infections and infestations	Active Treatment Phase: From Placebo to Laquinimod 1.2 mg	11	236	13
other	Respiratory tract infection viral	Infections and infestations	Placebo-Controlled Phase: Laquinimod 0.6 mg	32	727	54
other	Respiratory tract infection viral	Infections and infestations	Placebo-Controlled Phase: Laquinimod 1.2 mg	31	732	37
other	Respiratory tract infection viral	Infections and infestations	Placebo-Controlled Phase: Placebo	39	740	56
other	Respiratory tract infection viral	Infections and infestations	Active Treatment Phase: Early Laquinimod 0.6 mg	14	580	19

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01707992/events

API reference For AI assistants

Adverse events1,712

Sources 3

Read this list from software.